Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• To evaluate the long-term safety of GDC-0853 over an extended treatment period of up to 52 weeks • To evaluate the efficacy of GDC-0853 (analysed separately for methotrexate-inadequate response [MTX-IR] and tumour necrosis factor-inadequate response [TNF-IR] patients) at Week 52 relative to baseline in Study GA29350
Inclusion criteria
- Rheumatoid Arthritis